Added Benefit Of Eribulin In Breast Cancer Is Not Proven
Eribulin (trade name: HalavenĀ®) was approved in March 2011 for women with locally advanced or metastasizing breast cancer in whom the disease has progressed despite prior drug therapy...
More... |
All times are GMT -7. The time now is 12:25 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021